Treacher Collins syndrome: Unmasking the role of Tcof1/treacle

Daisuke Sakaia, Paul A. Trainor

Abstract

Treacher Collins syndrome (TCS) is a rare congenital birth disorder characterized by severe craniofacial defects. The syndrome is associated with mutations in the TCOF1 gene which encodes a putative nucleolar phosphoprotein known as treacle. An animal model of the severe form of TCS, generated through mutation of the mouse homologue Tcof1 has recently revealed significant insights into the etiology and pathogenesis of TCS (Dixon and Dixon, 2004; Dixon et al., 2006; Jones et al., 2008). During early embryogenesis in a TCS individual, an excessive degree of neuroepithelial apoptosis diminishes the generation of neural crest cells. Neural crest cells are a migratory stem and progenitor cell population that generates most of the tissues of the head including much of the bone, cartilage and connective tissue. It has been hypothesized that mutations in Tcof1 disrupt ribosome biogenesis to a degree that is insufficient to meet the proliferative needs of the neuroepithelium and neural crest cells. This causes nucleolar stress activation of the p53-dependent apoptotic pathway which induces neuroepithelial cell death. Interestingly however, chemical and genetic inhibition of p53 activity can block the wave of apoptosis and prevent craniofacial anomalies in Tcof1 mutant mice (Jones NC, Lynn ML, Gaudenz K, Sakai D, Aoto K, Rey JP, et al. Prevention of the neurocristopathy Treacher Collins syndrome through inhibition of p53 function. Nat Med 2008;14:125–33). These findings shed new light on potential therapeutic avenues for the prevention of not only TCS but also other congenital craniofacial disorders which share a similar etiology and pathogenesis.

1. Introduction

Craniofacial abnormalities are a recognized component of approximately one-third of all congenital birth defects (Gorlin et al., 1990). Treacher Collins syndrome (TCS, OMIM number 154500) is one of the most severe congenital disorders of craniofacial development and is extremely rare, occurring with an incidence of 1 in 50,000 live births. TCS was first described by Treacher Collins in 1900 after observation of two individuals with similar facial abnormalities (Treacher Collins, 1900). Subsequently in 1940, Franceschetti and Klein (1949) described the condition based on their own observations as mandibulofacial dysostosis. Characteristic abnormalities associated with TCS/mandibulofacial dysostosis include cleft palate, hypoplasia of the facial bones, particularly the mandible and zygomatic complex, downward slanting of the palpebral fissures with colobomas of the lower eyelids and deformity of the external ear. Other clinical features of TCS may include conductive hearing loss (Phelps et al., 1981) along with defects in brain development such as microcephaly and mental retardation. The gene responsible for TCS was identified on chromosome 5 and named TCOF1 (Treacher Collins Syndrome Collaborative Group, 1996). The identification of all 26 exons of TCOF1 has unveiled more than 100 family specific mutations which include splicing mutations, insertions, missense and nonsense mutations as well as deletions. TCS is an autosomal dominant disorder and molecular analysis of the TCOF1 gene has determined that 40% of infants born with TCS have inherited one mutated copy of TCOF1 while 60% arise as the result of de novo mutations (Splendore et al., 2003). The majority of mutations result in truncated proteins suggesting the importance of the C-terminal domain for Treacle function. Although there are inter- and intrafamilial variations ranging from mild to severe, there is no genotype/phenotype correlation.

2. Pathogenesis

Neural crest cells are a multipotent, stem and progenitor cell population, formed in the neural ectoderm at the boundary with non-neural ectoderm along the entire body axis during early embryogenesis. Neural crest cells undergo an epithelial–mesenchymal transition and in the cranial region, these cells delaminate from the neural ectoderm and concomitant with their expression of Sox10 (Fig. 1), they migrate over extensive distances to the periphery of the face giving rise to most of the cartilage, bone,
connective and peripheral nervous tissues in the head (Noden, 1983; Couly et al., 1998; Chai et al., 2000). Most disorders of craniofacial development are thought to be caused by defects in the formation, proliferation, migration, and/or differentiation of cranial neural crest cells. TCS is no exception as almost all of the cranioskeletal anomalies characteristically observed in TCS individuals involve tissues which are derived from neural crest cells. Hence abnormal neural crest migration, ectopic cell death and inappropriate differentiation have all been hypothesized as underlying causes of TCS (Wiley et al., 1983; Sulik et al., 1987; Poswillo, 1988; Sulik et al., 1988). However, until recently there was little experimental cellular or biochemical evidence to support any of these mechanistic hypotheses.

To precisely understand the pathogenetic mechanism of TCS, it is essential to elucidate the cellular and biochemical function of Treacle, the protein encoded by TCOF1. Treacle is a relatively simple 144 kDa protein that consists of at least three distinct domains, including unique amino and carboxy termini and a characteristic central repeat domain (Dixon et al., 1997; Wise et al., 1997). Putative nuclear export and import signals are seen at the N-terminus and C-terminus, respectively. It has been reported that the C-terminal domain is important for nucleolar localization of treacle (Marsh et al., 1998), and that perhaps the intracellular localization of treacle is very dynamic. Within the central domain, treacle contains multiple casein kinase II and protein kinase C phosphorylation site repeats. This is consistent with the fact that treacle is highly phosphorylated and associates with casein kinase II in vitro (Isaac et al., 2000). However, to date it has not been determined if phosphorylation is required for normal treacle function nor if it plays an important role in its subcellular localization.

Immunofluorescence studies have revealed that treacle co-localizes with upstream binding factor (UBF) and RNA polymerase I in the nucleolus (Valdez et al., 2004). Furthermore, biochemical analyses of treacle via in vitro siRNA-mediated knockdown demonstrated that treacle is essential for the proper transcription of rDNA, which is consistent with its structural homology to Nopp140, another nucleolar protein which also regulates rDNA transcription (Chen et al., 1999). Treacle has also been identified as a constituent of human Nop56-associated pre-ribosomal ribonucleoprotein (pre-rRNPs) complexes (Hayano et al., 2003) that 2′-O-methylate pre-ribosomal RNA during the early stages of pre-rRNA processing in the nucleolus (Valdez et al., 2004). These data imply that treacle is contained within an RNP complex in the nucleolus and may be specifically involved in governing the ribosome biogenesis process.

Recently an essential role for treacle, in ribosome biogenesis was demonstrated in vivo (Dixon et al., 2006). Mice haploinsufficient for Tcof1 exhibited diminished mature ribosome production as measured by the levels of 28S rRNA. This deficiency was observed in the neural ectoderm as well as in the neural crest but not in tissues such as the endoderm implying that treacle may function as a tissue-specific regulator of ribosome biogenesis (Dixon et al., 2006). The deficiency in ribosome biogenesis correlated with decreased proliferation in both the neural ectoderm and neural crest cells observed in Tcof1 mutants. Consequently it has been hypothesized that deficient ribosome biogenesis is insufficient to meet the cellular and metabolic needs of these highly proliferative cell populations during embryogenesis and more specifically it is directly responsible for the high levels of cell death observed in the neural ectoderm at the time of neural crest formation (Dixon et al., 2006). Since the neural ectoderm cells are the precursors of the neural crest it is not surprising that the generation of neural crest cells is impaired. Furthermore, this can account for the characteristic hypoplasia of cranioskeletal elements observed in TCS individuals (Fig. 1).

The majority of mutations identified in humans are predicted to result in 3′ truncations of treacle and loss of the nuclear import signals. This firmly implies that the nuclear and nucleolar subcellular localization of treacle is critical to its ribosome biogenesis functions and moreover that ribosome biogenesis and consequently neural crest cell formation are similarly impaired in TCS patients.

3. Therapy

Infants with moderate or severe hypoplasia of the mandible and zygomatic complex typically have cleft palate along with narrowed airways and consequently experience major breathing and feeding problems. The majority of these patients will require surgery to correct their airway obstruction and may also require more complex craniofacial reconstruction to improve their appearance and function.

Fig. 1. Labelling of e18.5 and e19.5 wild type (A and C) and Tcof1−/− (B and D) mouse embryos via in situ hybridization with a Sox10 riboprobe which is commonly used to mark migrating neural crest cells. Arrows highlight the decrease in the number of neural crest cells in TCS affected embryos. Alizarin red and alcian blue staining of bone and cartilage, respectively, in e18.5 wild type (E) and Tcof1−/− (F) embryos demonstrating the cranioskeletal hypoplasia characteristic of Treacher Collins syndrome that manifests from the earlier neural crest cell deficit. f, frontal; md, mandibular; mx, maxillary; n, nasal; and t, temporal bones (unpublished photos from the Trainor lab).
problems. In severe cases many newborn infants will require an immediate tracheostomy. At defined ages or when specific developmental milestones have been reached, extensive plastic surgery can help to restore the structure of the face. Bone grafts can be performed to build up the underdeveloped facial bones such as those surrounding the eyes. The ears can also be reconstructed and together with implantation of conductive auditory aids, hearing can be restored. Mandibular distraction can be performed to lengthen the jaw which can alleviate critical breathing and feeding problems and may also improve appearance as well. It is important to stress that the care of individuals affected by TCS requires a multidisciplinary approach and may involve intervention from a number of healthcare professionals both pre- and post-operatively. Excellent outcomes are achievable through a comprehensive, well-coordinated and integrated treatment plans incorporating craniofacial surgeons, orthodontists, ophthalmologists, otolaryngologists and speech pathologists. However, the results are often variable and may not be fully corrective, hence considerable effort should also be invested into examining therapeutic avenues of prevention.

In this regard, a recent study has not only deepened our understanding of the etiology and pathogenesis of TCS but more importantly has shed new light on potential avenues for the therapeutic prevention of TCS (Jones et al., 2008). Using a mouse model of TCS, it was discovered that p53 protein was activated and stabilized in the neuroepithelium of mutant embryos, and furthermore, that numerous p53-responsive pro-apoptotic genes, such as Ccn1, Tp53inp1, Puma1, Perp and Wig1, were also ectopically expressed in the neuroepithelium correlating with the high levels of neuroepithelium-specific cell death observed in Tcof1 mutants. Previously, it has been well established that p53 is a tumor suppressor gene that functions in many critical events such as cell cycle regulation, DNA damage, centrosome amplification and apoptosis (Levine, 1997). Interestingly, nucleolar stress can also induce the activation of a p53-dependent checkpoint and subsequent cell cycle arrest and apoptosis (Rubi and Milner, 2003). This suggests that haploinsufficiency of treacle which results in deficient ribosome biogenesis probably causes nucleolar stress activation and stabilization of p53. This in turn leads to the activation of numerous pro-apoptotic genes which can account for the high degree of neuroepithelial-specific apoptosis observed in Tcof1 mutants.

This finding raises the possibility that inhibition of p53 activity may be able to block neuroepithelial apoptosis, restore the neural crest cell population and prevent the craniofacial anomalies characteristic of TCS. Indeed, in Tcof1<sup>+/−</sup> embryos treated in utero with pifithrin-α (a specific inhibitor of p53 activity), a dose- and exposure-dependent inhibition of neuroepithelial apoptosis and rescue of craniofacial development was observed (Jones et al., 2008). A similar but more efficient rescue was also observed when p53 activity was blocked genetically. Removal of one or two copies of the Tcof1<sup>+/−</sup> background revealed a dose-dependent inhibition of neuroepithelial apoptosis and prevention of craniofacial anomalies characteristic of TCS. This study by Jones et al. (2008) possibly represents the first successful rescue of a congenital neurocristopathy and provides an attractive model for the prevention of other craniofacial birth defects of similar etiology and pathogenesis involving neuroepithelial apoptosis.

However, a major caveat to inhibition of p53 as a therapeutic avenue for prevention of craniofacial anomalies is that p53 performs a number of important cellular functions not least of which is its role as a tumor suppressor. The loss of p53 frequently results in tumor formation and in fact 75% of p53<sup>−/−</sup> mice develop tumors within 3–6 months (Donehower et al., 1992). Therefore, it is essential to interrogate the downstream effectors of p53-dependent apoptosis, specifically the genes without any link to cancer and tumor progression as potential minimal risk candidates for the therapeutic prevention of TCS and other craniofacial syndromes.

Despite rescuing the craniofacial defects through inhibition of p53, ribosome biogenesis was still surprisingly impaired in Tcof1<sup>+/−</sup> mutants. This implies firstly that deficient ribosome biogenesis alone is not sufficient to generate the Treacher Collins syndrome phenotype. Secondly, deficient ribosome biogenesis may not be the trigger responsible for activation of the p53 and subsequent neuroepithelial apoptosis. Thirdly, there may be other non-ribosomal or non-nuclear functions for treacle during embryogenesis. In this regard, it was recently determined by in silico analysis that the N-terminus of Treacle contains a LisH motif which shares homology with the N-terminal region of Lis1 (Enmes and Ponting, 2001). This motif contributes to microtubule binding, dimerization, protein half-life and localization (Gerlitz et al., 2005). This suggests that in addition to any nuclear import and export signals, the LisH motif may also be important for the dynamic localization of treacle. Furthermore, it may also be critical for as yet undiscovered functions of treacle which must be fully explored in order to fully appreciate the etiology and pathogenesis of TCS. The potential outcomes of course include providing a better understanding of the roles of Tcof1 during embryogenesis and also possibly identifying other therapeutic avenues for the prevention and repair of TCS and other craniofacial malformation syndromes.

### References


